
Cyllene Therapeutics has raised €33m in Series C financing to support later-stage development of EG110A, an investigational genetic medicine for …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

